Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

Autor: Herben, VMM, ten Bokkel Huinink, WW, Dubbelman, AC, Mandjes, IAM, Groot, Y, van Gortel-van Zomeren, DM, Beijnen, JH, Herben, V M, ten Bokkel Huinink, W W, Dubbelman, A C, Mandjes, I A, van Gortel-van Zomeren, D M, Beijnen, J H

Publikováno v: British Journal of Cancer; Dec1997, Vol. 76 Issue 11, p1500-1508, 9p

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

Autor: Nederlof I; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Isaeva OI; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Graaf M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Gielen RCAM; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Bakker NAM; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Rolfes AL; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Garner H; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Boeckx B; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Traets JJH; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Maaker M; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Brussel T; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Chelushkin M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Champanhet E; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lopez-Yurda M; Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van de Vijver K; Department of Pathology, UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium.; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van den Berg JG; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Klioueva N; Department of Pathology, OLVG Hospital, Amsterdam, the Netherlands., Mann RM; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Loo CE; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Duijnhoven FH; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Skinner V; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Luykx S; Medical Oncology Department, Tergooi Hospital - locatie Hilversum, Hilversum, the Netherlands., Kerver E; Department of Oncology, OLVG Hospital, Amsterdam, the Netherlands., Kalashnikova E; Natera, San Carlos, CA, USA., van Dongen MGJ; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Linn SC; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Blank CU; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Visser KE; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands., Salgado R; Department of Pathology, ZAS hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Wessels LFA; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Drukker CA; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Schumacher TN; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands., Horlings HM; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lambrechts D; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Kok M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.

Publikováno v: Nature medicine [Nat Med] 2024 Nov; Vol. 30 (11), pp. 3223-3235. Date of Electronic Publication: 2024 Sep 16.

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

Autor: Geurts VCM; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Voorwerk L; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Balduzzi S; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Salgado R; Department of Pathology, ZAS, Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Center, Melbourne, Victoria, Australia., Van de Vijver K; Department of Pathology, University Hospital Ghent, Cancer Research Institute Ghent (CRIG), Ghent, Belgium., van Dongen MGJ; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kemper I; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Heuver M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Sparreboom W; Astra Zeneca, The Hague, the Netherlands., Haanen JBAG; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Horlings HM; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kok M; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: M.Kok@nki.nl.

Publikováno v: Breast (Edinburgh, Scotland) [Breast] 2023 Aug; Vol. 70, pp. 76-81. Date of Electronic Publication: 2023 Jun 27.

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

Autor: Kester L; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute-The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute-Hubrecht Institute- KNAW & University Medical Centre Utrecht, Utrecht, the Netherlands., Seinstra D; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute-The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Rossum AGJ; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Vennin C; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute-The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hoogstraat M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute-The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Velden D; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Opdam M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hahn K; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute-The Netherlands Cancer Institute, Amsterdam, the Netherlands., Nederlof I; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lips EH; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Data Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Leeuwen-Stok AE; Dutch Breast Cancer Research Group, BOOG Study Center, Amsterdam, the Netherlands., Canisius S; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Tinteren H; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Imholz ALT; Department of Medical Oncology, Deventer Ziekenhuis, Deventer, the Netherlands., Portielje JEA; Department of Medical Oncology, HagaZiekenhuis, The Hague, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Bos MEMM; Department of Internal Oncology, Reinier de Graaf Gasthuis, Delft, the Netherlands., Bakker SD; Department of Medical Oncology, Zaans Medisch Centrum, Zaandam, the Netherlands., Rutgers EJ; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Horlings HM; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Diagnostic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Voest EE; Oncode Institute-The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wessels LFA; Oncode Institute-The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kok M; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Oosterkamp HM; Department of Medical Oncology, Haaglanden Medisch Centrum, Den Haag, the Netherlands., van Oudenaarden A; Oncode Institute-Hubrecht Institute- KNAW & University Medical Centre Utrecht, Utrecht, the Netherlands., Linn SC; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, University Medical Center, Utrecht, the Netherlands., van Rheenen J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute-The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Molecular Cancer Research, Center Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Mar 01; Vol. 28 (5), pp. 960-971.